Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations
Identifieur interne : 009053 ( Main/Exploration ); précédent : 009052; suivant : 009054Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations
Auteurs : V. Launay-Vacher [France] ; E. Chatelut [France] ; Sm Lichtman [États-Unis] ; H. Wildiers [Belgique] ; C. Steer [Australie] ; M. Aapro [Suisse, Niger]Source :
- Annals of Oncology [ 0923-7534 ] ; 2007-07-13.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Cancer, Personne âgée, Recommandation.
English descriptors
- KwdEn :
Abstract
Background: Elderly cancer patients commonly have renal function decline. This warrants particular caution during the administration of renally excreted cancer drugs or those with established nephrotoxicity. Design: An International Society for Geriatric Oncology task force was formed to discuss treatment recommendations for this group of patients. Results: Before drug therapy, the assessment and optimization of hydration status and evaluation of renal function is required. Serum creatinine alone is insufficient as a means of evaluating renal function, and creatinine clearance should at least be calculated in every patient by the abbreviated modification of diet in renal disease or Cockcroft-Gault equations. In the extremes of obesity and cachexia and at very high and low creatinine values, no single tool is really accurate. In these patients, the best estimate of glomerular filtration rate is provided by direct methods such as 51Cr-EDTA or inulin measurement. Within each drug class, preference may be given to agents less likely to be influenced by renal clearance, which are minimally nephrotoxic, or for which appropriate methods of prevention for renal toxicity exist. Coadministration of known nephrotoxic drugs should be avoided or minimized. Conclusions: Future trials should be designed to present data in a way that allows evaluation of the contribution of renal function to toxicity and efficacy.
Url:
DOI: 10.1093/annonc/mdm011
Affiliations:
- Australie, Belgique, France, Niger, Suisse, États-Unis
- Midi-Pyrénées, Occitanie (région administrative), État de New York, Île-de-France
- Paris, Toulouse
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001704
- to stream Istex, to step Curation: 001704
- to stream Istex, to step Checkpoint: 001291
- to stream Main, to step Merge: 009A26
- to stream PascalFrancis, to step Corpus: 003989
- to stream PascalFrancis, to step Curation: 002699
- to stream PascalFrancis, to step Checkpoint: 003663
- to stream Main, to step Merge: 009D75
- to stream Main, to step Curation: 009053
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations</title><author><name sortKey="Launay Vacher, V" sort="Launay Vacher, V" uniqKey="Launay Vacher V" first="V" last="Launay-Vacher">V. Launay-Vacher</name></author><author><name sortKey="Chatelut, E" sort="Chatelut, E" uniqKey="Chatelut E" first="E" last="Chatelut">E. Chatelut</name></author><author><name sortKey="Lichtman, Sm" sort="Lichtman, Sm" uniqKey="Lichtman S" first="Sm" last="Lichtman">Sm Lichtman</name></author><author><name sortKey="Wildiers, H" sort="Wildiers, H" uniqKey="Wildiers H" first="H" last="Wildiers">H. Wildiers</name></author><author><name sortKey="Steer, C" sort="Steer, C" uniqKey="Steer C" first="C" last="Steer">C. Steer</name></author><author><name sortKey="Aapro, M" sort="Aapro, M" uniqKey="Aapro M" first="M" last="Aapro">M. Aapro</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:79EDC5BA72709253FBFA696FFE2FA3D2614D3E9C</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1093/annonc/mdm011</idno><idno type="url">https://api.istex.fr/document/79EDC5BA72709253FBFA696FFE2FA3D2614D3E9C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001704</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001704</idno><idno type="wicri:Area/Istex/Curation">001704</idno><idno type="wicri:Area/Istex/Checkpoint">001291</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001291</idno><idno type="wicri:doubleKey">0923-7534:2007:Launay Vacher V:renal:insufficiency:in</idno><idno type="wicri:Area/Main/Merge">009A26</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:07-0422143</idno><idno type="wicri:Area/PascalFrancis/Corpus">003989</idno><idno type="wicri:Area/PascalFrancis/Curation">002699</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003663</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">003663</idno><idno type="wicri:doubleKey">0923-7534:2007:Launay Vacher V:renal:insufficiency:in</idno><idno type="wicri:Area/Main/Merge">009D75</idno><idno type="wicri:Area/Main/Curation">009053</idno><idno type="wicri:Area/Main/Exploration">009053</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations</title><author><name sortKey="Launay Vacher, V" sort="Launay Vacher, V" uniqKey="Launay Vacher V" first="V" last="Launay-Vacher">V. Launay-Vacher</name><affiliation wicri:level="3"><country>France</country><placeName><settlement type="city">Paris</settlement><region type="région" nuts="2">Île-de-France</region></placeName><wicri:orgArea>Hôpital Pitié-Salpêtrière</wicri:orgArea></affiliation></author><author><name sortKey="Chatelut, E" sort="Chatelut, E" uniqKey="Chatelut E" first="E" last="Chatelut">E. Chatelut</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Université Paul-Sabatier and Institut Claudius-Regaud, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Lichtman, Sm" sort="Lichtman, Sm" uniqKey="Lichtman S" first="Sm" last="Lichtman">Sm Lichtman</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Sloan-Kettering Cancer Center, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Wildiers, H" sort="Wildiers, H" uniqKey="Wildiers H" first="H" last="Wildiers">H. Wildiers</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>University Hospital Gasthuisberg, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Steer, C" sort="Steer, C" uniqKey="Steer C" first="C" last="Steer">C. Steer</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Murray Valley Private Hospital, Wodonga</wicri:regionArea><wicri:noRegion>Wodonga</wicri:noRegion></affiliation></author><author><name sortKey="Aapro, M" sort="Aapro, M" uniqKey="Aapro M" first="M" last="Aapro">M. Aapro</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Clinique de Genolier, Geneva</wicri:regionArea><wicri:noRegion>Geneva</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Niger</country></affiliation><affiliation><wicri:noCountry code="syntax">???</wicri:noCountry></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Niger</country></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Oncology</title><idno type="ISSN">0923-7534</idno><idno type="eISSN">1569-8041</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2007-07-13">2007-07-13</date><biblScope unit="volume">18</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1314">1314</biblScope><biblScope unit="page" to="1321">1321</biblScope></imprint><idno type="ISSN">0923-7534</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0923-7534</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cancer</term><term>Cancerology</term><term>Clearance</term><term>Creatinine</term><term>Elderly</term><term>Geriatrics</term><term>International</term><term>Malignant tumor</term><term>Recommendation</term><term>Renal failure</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Cancer</term><term>Cancérologie</term><term>Clairance</term><term>Créatinine</term><term>Gériatrie</term><term>Insuffisance rénale</term><term>International</term><term>Personne âgée</term><term>Recommandation</term><term>Tumeur maligne</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Cancer</term><term>Personne âgée</term><term>Recommandation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">Background: Elderly cancer patients commonly have renal function decline. This warrants particular caution during the administration of renally excreted cancer drugs or those with established nephrotoxicity. Design: An International Society for Geriatric Oncology task force was formed to discuss treatment recommendations for this group of patients. Results: Before drug therapy, the assessment and optimization of hydration status and evaluation of renal function is required. Serum creatinine alone is insufficient as a means of evaluating renal function, and creatinine clearance should at least be calculated in every patient by the abbreviated modification of diet in renal disease or Cockcroft-Gault equations. In the extremes of obesity and cachexia and at very high and low creatinine values, no single tool is really accurate. In these patients, the best estimate of glomerular filtration rate is provided by direct methods such as 51Cr-EDTA or inulin measurement. Within each drug class, preference may be given to agents less likely to be influenced by renal clearance, which are minimally nephrotoxic, or for which appropriate methods of prevention for renal toxicity exist. Coadministration of known nephrotoxic drugs should be avoided or minimized. Conclusions: Future trials should be designed to present data in a way that allows evaluation of the contribution of renal function to toxicity and efficacy.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Belgique</li><li>France</li><li>Niger</li><li>Suisse</li><li>États-Unis</li></country><region><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li><li>État de New York</li><li>Île-de-France</li></region><settlement><li>Paris</li><li>Toulouse</li></settlement></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Launay Vacher, V" sort="Launay Vacher, V" uniqKey="Launay Vacher V" first="V" last="Launay-Vacher">V. Launay-Vacher</name></region><name sortKey="Chatelut, E" sort="Chatelut, E" uniqKey="Chatelut E" first="E" last="Chatelut">E. Chatelut</name></country><country name="États-Unis"><region name="État de New York"><name sortKey="Lichtman, Sm" sort="Lichtman, Sm" uniqKey="Lichtman S" first="Sm" last="Lichtman">Sm Lichtman</name></region></country><country name="Belgique"><noRegion><name sortKey="Wildiers, H" sort="Wildiers, H" uniqKey="Wildiers H" first="H" last="Wildiers">H. Wildiers</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Steer, C" sort="Steer, C" uniqKey="Steer C" first="C" last="Steer">C. Steer</name></noRegion></country><country name="Suisse"><noRegion><name sortKey="Aapro, M" sort="Aapro, M" uniqKey="Aapro M" first="M" last="Aapro">M. Aapro</name></noRegion></country><country name="Niger"><noRegion><name sortKey="Aapro, M" sort="Aapro, M" uniqKey="Aapro M" first="M" last="Aapro">M. Aapro</name></noRegion><name sortKey="Aapro, M" sort="Aapro, M" uniqKey="Aapro M" first="M" last="Aapro">M. Aapro</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 009053 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 009053 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:79EDC5BA72709253FBFA696FFE2FA3D2614D3E9C
|texte= Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations
}}
| This area was generated with Dilib version V0.6.33. |  |